Opinion: Control vs. eradication: Applying infectious disease treatment strategies to cancer

Clinical treatment for metastatic cancer has traditionally entailed administering the highest possible dose in the shortest period, a strategy known as high-dose density therapy. The implicit goal is complete eradication. Unfortunately, a systemic cure for most metastatic cancers remains elusive, and the role of chemotherapy has been reduced to prolonging life and ameliorating symptoms.

[1]  B. Frieden,et al.  Adaptive therapy. , 2009, Cancer research.

[2]  Bonnie F. Sloane,et al.  Bicarbonate increases tumor pH and inhibits spontaneous metastases. , 2009, Cancer research.

[3]  P. Visca,et al.  Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity , 2013, Proceedings of the National Academy of Sciences.

[4]  Robert J Gillies,et al.  The potential role of systemic buffers in reducing intratumoral extracellular pH and acid-mediated invasion. , 2009, Cancer research.

[5]  Patrick Emery,et al.  Cryptochromes Define a Novel Circadian Clock Mechanism in Monarch Butterflies That May Underlie Sun Compass Navigation , 2008, PLoS biology.

[6]  J. Salk.  Clonal evolution in cancer , 2010 .

[7]  J. Pepper,et al.  Drugs that target pathogen public goods are robust against evolved drug resistance , 2012, Evolutionary applications.

[8]  J. Pepper.  Defeating Pathogen Drug Resistance: Guidance from Evolutionary Theory , 2008, Evolution; international journal of organic evolution.

[9]  David Laehnemann,et al.  When the Most Potent Combination of Antibiotics Selects for the Greatest Bacterial Load: The Smile-Frown Transition , 2013, PLoS biology.

[10]  Stephanie Forrest,et al.  Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  Troy Day,et al.  The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy , 2011, Proceedings of the National Academy of Sciences.

[12]  M. Stahlhut,et al.  Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. , 1988, Cancer research.

[13]  Sam P. Brown,et al.  Gallium-mediated siderophore quenching as an evolutionarily robust antibacterial treatment , 2014, Evolution, medicine, and public health.

[14]  V. Sperandio,et al.  Anti-virulence strategies to combat bacteria-mediated disease , 2010, Nature Reviews Drug Discovery.

[15]  Stephen P. Diggle,et al.  Quorum Sensing and the Social Evolution of Bacterial Virulence , 2009, Current Biology.

[16]  A. Read,et al.  Animal Defenses against Infectious Agents: Is Damage Control More Important Than Pathogen Control? , 2008, PLoS biology.

[17]  Stephen P. Diggle,et al.  Targeting virulence: can we make evolution-proof drugs? , 2014, Nature Reviews Microbiology.

[18]  N. Høiby,et al.  Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model. , 2012, The Journal of antimicrobial chemotherapy.

[19]  G. Tempera,et al.  Anti-Adhesion Activity of A2-type Proanthocyanidins (a Cranberry Major Component) on Uropathogenic E. coli and P. mirabilis Strains , 2014, Antibiotics.

[20]  T. Coenye,et al.  Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model , 2012 .

[21]  R. Gatenby.  A change of strategy in the war on cancer , 2009, Nature.